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Abstract. Malaria is one of problematic infectious diseases worldwide. The absence of an effective vaccine and the spread of drug resistant 
strains of Plasmodium clearly indicate the necessity for the deveploment of new chemotherapeutic agents. Recent method being developed is 
searching a new drug of antimalarial using in silico screening, or also known as virtual screening. One of enzyme target that important for 
growth of the malaria parasite is Plasmodium falciparum Enoyl Acyl Carrier Protein Reductase (PfENR). Inhibition of this enzyme cause the 
fatty acid biosynthesis type II will be terminated. In this research, in silico screening was performed using AUTODOCK VINA software to 
find inhibitor candidates of PfENR by using ligands from the database of Medicinal Plants in Indonesia. On the AUTODOCK VINA software 
moleculer docking experiments were performed between ligands and macromolecule target PfENR. This target that has been optimized with 
residue removal and charges addition. Ligand is expected to be the PfENR inhibitors. 
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1. Introduction 
Malaria is an infectious disease that can be found in 
almost all parts of the world, especially in tropical and sub-
tropical countries. According to the World Health 
Organization (WHO), in 2012 there was a spread of malaria 
in 99 countries from 104 countries which in the WHO data, 
Indonesia was one of the 99 countries (WHO, 2012). 
According to the Indonesian Ministry of Health's Directorate 
of Animal-Based Disease Control, in 2012 there were 
417,819 positive cases of malaria in Indonesia. 
The efforts made to control and eradicate malaria have 
been many, however, the disease has developed again due to 
increased cases of resistance to some antimalarial drugs, 
vector resistance to insecticides, and human migration from 
one region to another (Fauci et al, 2008) . More than 40% of 
the world's population lives in malaria endemic areas at risk 
of contracting malaria (Aguiar, 2012). Malaria can directly 
cause anemia and can reduce work productivity. This disease 
is also still endemic in most parts of Indonesia. According to 
2014 Ministry of Health data, the incidence of malaria in 
Indonesia in 2014 was 1%. The five provinces with the 
highest malaria incidence include Papua (29.57%), West 
Papua (20.85%), NTT (12.81%), Maluku (6.0%), and North 
Maluku (3.32 %) (Indonesian Ministry of Health. 2011). 
Malaria is an erythrocyte infectious disease caused by 
protozoan parasites from the Plasmodium genus. The 
protozoa enters the human body through the intermediaries 
of the female Anopheles mosquito. There are four 
Plasmodium species which commonly infect humans, that is 
P. falciparum, P. vivax, P. ovale and P. malariae. Of the four 
species, the most common cause of severe disease and even 
death is P. falciparum, the disease is commonly called 
tropical malaria / cerebral malaria (Katzung, 2006) while 
other species generally only cause fever and sometimes 
anemia (Fauci et al, 2008 & Brunton, 2006). 
To overcome infections caused by plasmodium, it is 
necessary to provide safe, effective, practical and 
economically affordable anti-malaria drugs to reduce deaths 
from malaria. There are several malaria drugs that are 
developed by inhibiting or killing the asexual forms of 
malaria parasites in human erythrocytes, such as quinine, 
chloroquine, pyrimethamine, sulfonamides, sulfones and 
artemisinin derivatives. To overcome infections caused by 
plasmodium, it is necessary to provide safe, effective, 
practical and economically affordable anti-malaria drugs to 
reduce deaths from malaria. There are several malaria drugs 
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that are developed by inhibiting or killing the asexual forms 
of malaria parasites in human erythrocytes, such as quinine, 
chloroquine, pyrimethamine, sulfonamides, sulfones and 
artemisinin derivatives. The problem is that lately the above 
drugs mostly fail in the healing process caused by parasites 
that become resistant to malaria drugs (Harijanto et al, 
2009). Some suspected causes of malaria resistance to 
antimalarials, in this case chloroquine is a parasite does not 
have an active side to bind to chloroquine so that 
chloroquine malaria drugs cannot be concentrated in 
erythrocytes (Pribadi & Muljono, 2004) 
Several enzymes that play an important role in the life 
cycle of plasmodium include haematin, hemozoin, 
plasmepsin, falsipain, falsicillin, dihydrofolate reductase, 
dihydroperoate synthase, Plasmodium falciparum Enoyl-
ACP reductase (PfENR), and others. Inhibition of these 
enzymes is a precursor to the development of antimalarial 
drugs (Sullivan & Krishna, 2005). 
In the last decade, there have been potential targets for 
antimalarials. This target is the type II fatty acid biosynthesis 
pathway that takes place in Plasmodium falciparum, with a 
specific target of Plasmodium falciparum Enoyl Acyl Carrier 
Protein Reductase (PfENR). This target was chosen because 
it has an important role in the synthesis of fatty acids in the 
Plasmodium falciparum body (Tasdemir, 2006). 
For developing countries such as Indonesia, this clearly 
requires its own strategy so that the discovery of new drugs 
that are useful for the community can be achieved but not 
costly. These efforts are not only carried out by parties 
engaged in the economic sector, but also by scientists and 
technologists. Today there is an alternative way to find new 
drugs raised by computer experts and information 
technology.  During this time the drugs were tested before 
being marketed using the in vitro and in vivo methods, 
whereas now the third method that is no less important is the 
in silico method or inside the computer. The use of 
computers in the discovery of new drugs aims to improve the 
efficiency of the simulation process and calculations in drug 
design. The computer offers an in silico method as a 
complement to in vitro and in vivo methods commonly used 
in drug discovery processes. The science that plays a role in 
this process is bioinformatics. One branch of bioinformatics 
is in silico screening or in silico screening, which involves a 
database with relevant molecular structures that are tethered 
to the target protein. The assessment results are then used as 
identification of structures with potential further 
physiological bonds and activities that can be evaluated in 
experiments (Pripp, 2006). 
In this study, an analysis of the mechanism and 
interaction between Plasmodium falciparum Enoyl Acyl 
Carrier Protein Reductase (PfENR) and ligands will act as an 
inhibitor through the in silico study method. The ligand used 
was derived from the results of screening from the Plant 
Chemical Database that has be done before. Based on the 
results of in silico antimalarial screening using the 
Indonesian Medicinal Plant Database on the target enzyme 
Plasmodium falciparum Enoyl Acyl Carrier Protein 
Reductase (PfENR). These chemical compounds are 
Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside 
or known as tea plants (Berwi, 2011). The compound is 
examined for its bonding ability with enzymes through 
bond-free energy (ΔG) and the resulting inhibition constant 
(Ki). The in silico method that will be carried out to examine 
these interactions is by molecular docking. This method is 
also used to save costs and time needed during research. 
(Wolff, 1996) 
 
2. Materials And Methods 
The material used is a two-dimensional structure of the 
Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside 
ligand or tea plant is known that you get online on the 
database https://pubchem.ncbi.nlm.nih.gov/. While the 
macromolecule file selected as the receptor is the enzyme 
Plasmodium falciparum Enoyl Acyl Carrier Protein 
Reductase (PfENR) with the code 1NHG which can be 
downloaded from the Bank Data Protein (GDP) database at 
the site http://www.rscb.org. The tool used consists of 
hardware and software. The hardware consists of a computer 
with the HP Pavilion dv2 laptop specifications (Amd Athlon 
neo dual core, 2GB ddr2 RAM, 250 seagate HDD, and VGA 
ati radeon x1200). The software used consists of Autodock 
Vina, ADT 1.5.6 (The Scripps Research Institute, America, 
LigPlot + 4.5.3 (Rowan Lawkowski), OS. Ubuntu 14.04 lts. 
 
Receptor Identification 
The protein used as a receptor is the enzyme Plasmodium 
falciparum Enoyl Acyl Carrier Protein Reductase (PfENR) 
(GDP code: 1nhg) which was obtained online through the 
site http://www.rscb.org/pdb (Figure 1). The identification 
process was carried out using Discovery Studio Visualizer 
4.0 software based on information obtained from the 1nhg 
coded Plasmodium falciparum Enoyl Acetyl Carrier Protein 
Reductase (PfENR) crystallization data conducted by 
Perozzo et al. (2002). 
 
3D Receptor Structure Geometry Optimization 
The 1nhg-coded receptor contains the coordinates of all 
residual atoms, crystallographic structural factors and XRD 
experimental data from the Plasmodium falciparum Enoyl 
Acyl Carrier Protein Reductase (PfENR) enzyme so that it 
can determine the quality of the protein three-dimensional 
structure. The geometry optimization process was done with 
ADT 1.5.6 software. The initial stage was the removal of 
water molecules (H2O) around proteins, hetero atoms and 
natural ligands. Next was the addition of Gasteiger and 
Hydrogen charges. Files were stored in PDBQT format. 
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3D Ligand Geometry Optimization 
The ligand that will be used is Kaempferol 3-rhamnosyl- (1-
3) -rhamnosyl- (1-6) -glucoside or known tea plants 
downloaded online at the database 
https://pubchem.ncbi.nlm.nih.gov/. The optimization process 
was done using ADT 1.5.6. The initial stage was nonpolar 
merged hydrogen gives Gasteiger charge and all files were 
stored in PDBQT format. 
  
Molecular docking process 
Grid Process and docking parameter validation are carried 
out with ADT 1.5.6, molecular docking is carried out with 
AutoDock Vina (Scripps Research Institute, USA) and it is 
assumed that all rotatable bonds (cyclic bonds) of ligands 
can rotate (flexible) and the receptor is fixed (rigid) ( Morris 
et al. 1998). The following parameters are parameters that 
have been validated. The selected grid box size is 64 x 52 x 
64 Å with spacing centered 1,000 Å at the receptor, center_x 
= 46,572, center_y = 82,254, center_z = 38,472 and the box 
area covers the entire receptor structure. Exaustiveness is set 
to number 8. The vina folder is placed on the C: \ Vina drive 
and then filled in the CONF.TXT file with the above 
parameters according to the center and size numbers. 
Execute the docking command using commands via the 
CMD window, call Vina.exe then type the command "C: \ 
vina --config conf.txt --log log.txt", then press enter and wait 
for the process to complete. Ligands that have the smallest 
Gibbs free energy (∆G) from the list are stored in PDBQT 
format (ADT 1.5.6) and converted to PDB format with DSV 
4.0. 
 
Analysis 
The docking results in the analysis of bond energy (∆G), 
hydrogen bond, RMSD value, binding residue, using Ligplot 
+ 4.5.3, for 2D visualization using DSV 4.0 and ADT 1.5.6. 
 
 
 
(a) (b) 
 
FIGURE 1. Visualization of 2D and 3D structures (a). Plasmodium falciparum receptor Enoyl Acyl Carrier Protein Reductase (PfENR) (b). 
Ligand of Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside compound 
 
3. Results And Discussion  
Receptor Identification 
Three-dimensional structure of the enzyme Plasmodium 
falciparum Enoyl Acyl Carrier Protein Reductase (PfENR) 
downloaded through the Protein Data Bank. Three-
dimensional structure of Plasmodium falciparum Enoyl Acyl 
Carrier Protein Reductase (PfENR) enzyme, from the results 
of crystallization carried out by Perozzo et al. (2002) coded 
PDB of 1nhg. Visualization of PDB 1nhg coded protein is 
done using DSV 4.0 software. The visualization results show 
that there are 4 chains, namely A, B, C and D and there are 
two natural ligands of TCL and NAD (Figure 1). Both 
natural ligands must be removed because the enzyme that 
will be docking must be a pure enzyme. Furthermore, the 
Ligan used is Kaempferol 3-rhamnosyl-(1-3) -rhamnosyl- 
(1-6) -glucoside or tea plant known. 
Bonding Energy (Gibbs free energy) 
Gibbs free energy (ΔGbinding) is a parameter of 
conformational stability between ligands and receptors. 
Thermodynamically the metabolic reactions in the body take 
place exergonically and endergonically. Exergonic reaction 
is a reaction that produces Gibbs free energy, which is the 
energy used to work at a fixed temperature and pressure. 
Exergonic reactions cause the free energy of the reagent 
molecules to fall, because their free energy is released during 
the reaction (Nelson et al. 2008). Therefore, free energy 
products become lower than reagent free energy. The lower 
the free energy of a molecule, the more stable the molecule 
is and the reaction goes spontaneously. This is called 
thermodynamic equilibrium, the more negative the free 
energy the reaction will be more spontaneous or will quickly 
form a stable conformation (Nelson et al. 2008). The 
bonding energy of the molecular docking results for the 
Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside 
compound produces a final value of -12.4 kcal / mol 
consisting of 9 ligand modes. This means that the 
Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside 
compound is stable to be used as an inhibitor of the enzyme 
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Plasmodium falciparum Enoyl Acyl Carrier Protein 
Reductase (PfENR) because the lower the free energy of a 
molecule, the molecule the more stable and the reaction goes 
spontaneously. 
TABLE 1. The bond energy of the Ligan docking result 
Mode Affinity 
(kcal/mol) 
dist from best mode 
rmsd l.b. rmsd u.b 
1 - 13.4 0.000 0.000 
2 - 13.3 2.141 8.775 
3 - 13.3 1.152 3.452 
4 - 13.3 2.788 9.052 
5 - 12.7 2.926 9.106 
6 - 12.7 2.603 8.862 
7 - 12.7 2.424 9.173 
8 - 12.4 1.973 4.318 
9 - 12.4 1.379 2.193 
When viewed from the value of RMSD (Root Means 
Standart Deviation) the final value of RMSD from 
Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside 
is 1,375 Angstrom for RMSD 1.b and 2,193 Angstrom for 
RMSD u.b. This means that the Kaempferol 3-rhamnosyl- 
(1-3) -rhamnosyl- (1-6) -glucoside compound is stable to be 
used as a ligand because the RMSD value is below 2.5 
Angstrom. 
When viewed from the ligand obtained, two modes are 
most similar to the original ligand position and which is the 
mode with the best poses, mode 2 and mode 7. Therefore, 
the compound Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- ( 
1-6) -glucoside is stable to be used as a ligand of the enzyme 
receptor Plasmodium falciparum Enoyl Acyl Carrier Protein 
Reductase (PfENR). 
Hydrogen Bond 
Hydrogen bonds are intermolecular attractions or between 
dipoles formed between two partial charges with opposite 
polarity. Hydrogen bonds occur when an atom gives its 
hydrogen covalent bond (donor) to an electronegative atom 
(acceptor), such as oxygen in -OH (Ser, Thr, Tyr, 
carbohydrate), H2O and Nitrogen in -NH3 + (Lys, Arg) or -
NH - (found in many peptide bonds, Trp, His, Arg, 
nucleotide bases) are all types of donors (Jefrey & Mart 
1997). 
  
(a) (b) 
FIGURE 2. Pose Ligand compound Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside (a). Ligand Mode 2 and Mode 7 (b). Ligand 
Mode 2 and Mode 7 with reseptor 
 
Based on the hydrogen bond data obtained, then among 
the 9 ligand modes produced, mode 3 has the most hydrogen 
bonds, there are 3 hydrogen bonds that bind to the residues 
of Gly106, Tyr111, and Gly112. The next one that has a 
hydrogen bond 2 is mode 1 which is the hydrogen bond with 
a ligand and hydrogen bonds with a residue of Leu315. For 
ligands that have only 1 hydrogen bond present in mode 4 
ligand which has a hydrogen bond at Ser317 residue, mode 5 
has hydrogen bonds only at the residue Ala17 and mode 9 
which has 1 hydrogen bond at the residue of Ala217. 
Whereas in mode 2, mode 6, mode 7 and mode 8 do not have 
hydrogen bonds. The large number of hydrogen bonds 
determines the strength of the interaction. So that in ligand 
mode 3 is considered to have the highest stability between 
other fashion ligands. In addition, the overall ligand of 
Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside 
is stable to be used as an inhibitor in the enzyme 
Plasmodium falciparum Enoyl Acyl Carrier Protein 
Reductase (PfENR) because there are hydrogen bonds that 
will increase stability. 
Ligands Interaction and Receptors 
Hydrophobic interactions also play an important role in the 
stability of the ligand against the receptor. Hydrophobic 
interaction is an interaction that avoids the liquid 
environment and tends to group in the inner part of the 
globular protein structure to minimize interaction with water 
which can damage the structure of the protein and cause the 
enzyme to lose its activity (Lin & Brasseur 1995). In ligand 
mode 1, there are residues that form hydrophobic 
interactions, namely residues Leu315 and Ala217. From this 
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interaction it can be seen that the ligand Kaempferol 3-
rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside is stable to be 
used as an inhibitor in the enzyme Plasmodium falciparum 
Enoyl Acyl Carrier Protein Reductase (PfENR) because 
there are hydrophobic interactions that will increase stability. 
The visualization of electrostatic interactions has not been 
able to be done by the software used in the study. But this 
interaction can be analyzed through residues that tend to 
form electrostatic interactions. Electrostatic interaction is an 
interaction between atoms caused by polarity. This 
interaction is a weak and non-covalent interaction so that it 
is easy to escape, but in large numbers, this interaction can 
have a large influence on stability (Sharp & Honig 1990). 
Polar residues are charged at the receptor if the interaction 
with ligand mode 1 is observed, namely, Asp107. From this 
interaction it can be seen that the ligand of Kaempferol 3-
rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside is stable to be 
used as an inhibitor in the enzyme Plasmodium falciparum 
Enoyl Acyl Carrier Protein Reductase (PfENR) because 
there are electrostatic interactions that will increase stability. 
FIGURE 3. Hydrogen bonds Ligand compounds Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside (a). Ligan Mode 3 (b). Receptors 
and Ligand Mode 1 
 
 
 
 
FIGURE 4. Interaksi Ligan mode 1 senyawa Kaempferol 3-
rhamnosyl-(1-3)-rhamnosyl-(1-6)-glucoside dengan reseptor 
Plasmodium falciparum Enoyl Acyl Carrier Protein Reductase 
(PfENR 
 
CONCLUSION 
 Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -
glucoside compounds have good stability against the enzyme 
Plasmodium falciparum Enoyl Acyl Carrier Protein 
Reductase (PfENR. This is evident from the low bond 
energy, which is -12.4 kcal / mol which consists of 9 ligand 
modes.This means that the Kaempferol 3-rhamnosyl- (1-3) -
rhamnosyl- (1-6) -glucoside compound is stable to be used 
as an inhibitor of the Plasmodium falciparum Enoyl Acyl 
Carrier Protein Reductase (PfENR) enzyme because it is 
increasingly low in free energy of a molecule, the molecule 
is more stable and the reaction runs spontaneously, besides 
that, Kaempferol 3-rhamnosyl- (1-3) -rhamnosyl- (1-6) -
glucoside compound has a good bond between the ligand 
and the receptor stability of the enzyme Plasmodium 
falciparum Enoyl Acyl Carrier Protein Reductase (PfENR. 
The hydrogen bond formed is seen in three hydrogen bonds, 
namely at the residue of Gly106, Tyr111, and Gly112 in the 
3 ligand mode. The interaction between ligands and 
receptors is also formed a stable is seen in the hydrophobic 
interactions seen at Leu315 and Ala217 residues and 
electrostatic interactions at Asp107 residues. From this 
interaction it can be seen that the ligand of Kaempferol 3-
rhamnosyl- (1-3) -rhamnosyl- (1-6) -glucoside is stable to be 
used as an inhibitor in the enzyme Plasmodium falciparum 
 
 
(a) (b) 
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Enoyl Acyl Carrier Protein Reductase (PfENR) because 
there are electrostatic interactions that will increase stability. 
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